Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 27.07.2021 at 12:00 PM CEST
Settings

Settings

Goto Application

1. AR067628 - METODO 925, USO DE LIGANDO CANNABINOIDE ENDOGENO PARA EL TRATAMIENTO CON UN FARMACO ANTAGONISTA DEL RECEPTOR CANNABINOIDE 1 (CB1R)

Office
Argentina
Application Number P080102860
Application Date 02.07.2008
Publication Number 067628
Publication Date 21.10.2009
Publication Kind A1
IPC
A61P 3/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
04Anorexiants; Antiobesity agents
A61K 31/415
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4151,2-Diazoles
A61K 31/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
A61K 31/4453
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4453only substituted in position 1, e.g. propipocaine, diperodon
CPC
A61P 3/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
04Anorexiants; Antiobesity agents
G01N 33/948
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
94involving narcotics ; or drugs or pharmaceuticals, neurotransmitters or associated receptors
948Sedatives, e.g. cannabinoids, barbiturates
G01N 2800/02
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
02Nutritional disorders
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
Applicants WALZ, MICHAEL
Priority Data 60/947733 03.07.2007 US
Title
(ES) METODO 925, USO DE LIGANDO CANNABINOIDE ENDOGENO PARA EL TRATAMIENTO CON UN FARMACO ANTAGONISTA DEL RECEPTOR CANNABINOIDE 1 (CB1R)
Abstract
(ES)
Métodos de selección de pacientes (incluyendo medicina personalizada). Permite la selección mejorada de un paciente que necesita de tratamiento con un fármaco antagonista del receptor cannabinoide (CB) (CB1R), basado en los niveles de ligandos cannabinoides endógenos circulantes (endocannabinoides). Método para seleccionar un mamífero que necesita de un tratamiento para perder peso y/o mantener el peso y/o prevenir el aumento de peso con un fármaco antagonista de CB1R el cual comprende determinar el nivel de por lo menos un ligando cannabinoide endógeno circulante en el mamífero, mediante el cual se puede predecir una mayor probabilidad de respuesta al fármaco antagonista, este método de medicina personalizada incluye la capacidad de identificar pacientes que tienen mayor probabilidad de responder en forma favorable al tratamiento con un fármaco antagonista de CB1R y de identificar pacientes con menos probabilidades de responder al tratamiento farmacológico evitando de ese modo el tratamiento innecesario y cualquier efecto secundario que pueda estar asociado con dicho tratamiento ineficaz. Reivindicación 6: El uso de acuerdo con cualquiera de las reivindicaciones precedentes donde el ligando cannabinoide endógeno es AEA o 2-AG. Reivindicación 10: El uso de acuerdo con cualquiera de las reivindicaciones precedentes, donde el antagonista de CB1R se selecciona entre: rimonabant, taranabant, surinabant, CP945598 y SLV319.